ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10372	Companies
216173	Keywords
145882	Articles
114461	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/10/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petites cellules
OSE Immunotherapeutics lance l'étude internationale d'Artemia en Phase 3 pour Tedopi® contre le cancer du poumon non à petites cellules, aux États-Unis, Canada, Europe, Royaume-Uni, avec présentations aux conférences WCLC et ESMO

Phase 3 OSE Immunotherapeutics Vaccin Thérapeutique Tedopi Cancer Du Poumon Non À Petites Cellules
BRIEF

published on 07/01/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics Publishes Preclinical Efficacy Results for Lusvertikimab in ALL

Immunotherapy OSE Immunotherapeutics Preclinical Results Lusvertikimab Acute Lymphoblastic Leukemia
BRIEF

published on 07/01/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics publie les résultats précliniques d’efficacité du Lusvertikimab dans la LAL

Immunothérapie Lusvertikimab Leucémie Lymphoblastique Aiguë OSE Immunothérapie Résultats Précliniques
PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 10 months ago

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics announces publication of preclinical efficacy results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'. Collaboration with University Medical Center Schleswig-Holstein on targeting ALL patients

OSE Immunotherapeutics Lusvertikimab Acute Lymphoblastic Leukemia Blood Journal IL-7 Receptor Antagonist
PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 10 months ago

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’
OSE Immunotherapeutics publie des résultats précliniques prometteurs sur Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans 'Blood', ouvrant de nouvelles perspectives en immunothérapie pour les patients atteints de LAL

Immunothérapie Publication OSE Immunotherapeutics Lusvertikimab Leucémie Aiguë Lymphoblastique
BRIEF

published on 06/24/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics signe un accord stratégique avec MSK pour les thérapies par cellules CAR-T

OSE Immunotherapeutics Leucémie Memorial Sloan Kettering Cancer Center CAR-T IL-7R
BRIEF

published on 06/24/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 10 months ago

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R

Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 10 months ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF

published on 06/20/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics présente des données prometteuses sur la plateforme ARNm au congrès FOCIS

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique FOCIS 2024 IL-35

Accesswire

Published on 05/09/2026 at 01:55, 21 hours 17 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 21 hours 32 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 21 hours 42 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 23 hours 12 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/09/2026 at 19:05, 4 hours 7 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 2 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 3 hours ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 4 hours ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 1 day 4 hours ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 2 days 3 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 3 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 4 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 4 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 4 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE